when Roche announced that it wanted to buy the remaining shares of Genentech that it already doesnt own for $ 43.7 billion Roche currently owns 56% of Genentechs stock. More importantly, Roche doesnt have control of Genentechs board of directors nor does it influence corporate strategy or product development. Unlike many other pharma companies who have historicallypurchased biotechnology companies and then integrated them into existing corporate structures, Roche previously opted to buy controlling... read more
